TPM3 and neoplasm: [24] used a mice model to further explore the oncogenic potential of TPM3‐ALK, underscoring the therapeutic potential of targeting ALK with specific inhibitors, showing notable tumor regression when treated with PF‐2341066, an ALK inhibitor.